Results of the CONFIRM phase IIItrial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer
Annotation: Summary - The CONFIRM trial has shown a statistically significant increase in TTP for F500 compared with F250 in postemenopausal women, without increase in toxicity.